PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Bempedoic acid with ezetimibe - Lipid modification

PAD Profile : Bempedoic acid with ezetimibe - Lipid modification

Keywords :
Primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Nustendi

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 December 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a GREEN traffic light status for bempedoic Acid with ezetimibe in line with NICE guidance (TA694).

 Please follow the guidance in the SPC and the National Lipid Management pathway for advice on initial and onward monitoring requirements.

 Note: Anaemia is a common side-effect of bempedoic acid. For patients where a reduction in haemoglobin (Hb) may be of concern, consider a full blood count (FBC) at 3 months and annually thereafter. 

 

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More